# Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

> **NCT03866577** · PHASE1,PHASE2 · TERMINATED · sponsor: **Momenta Pharmaceuticals, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Immune Thrombocytopenic Purpura (ITP)

## Interventions

- **BIOLOGICAL:** Biological: M254
- **DRUG:** Placebo
- **BIOLOGICAL:** Intravenous immunoglobulin (IVIg)

## Key facts

- **NCT ID:** NCT03866577
- **Lead sponsor:** Momenta Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-21
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Study was terminated based on Sponsor decision.
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866577, "Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03866577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*